{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T16:42:51Z","timestamp":1786639371580,"version":"build-2736575974"},"posted":{"date-parts":[[2021]]},"group-title":"SSRN","reference-count":116,"publisher":"Elsevier BV","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Endemic human coronaviruses (hCoVs) 229E and OC43 cause respiratory disease with recurrent infections, while severe acute respiratory syndrome (SARS)-CoV-2 spreads across the world with impact on health and societies. Here, we report an image-based multicycle infection procedure with \u03b1-coronavirus hCoV 229E-eGFP in an arrayed chemical library screen of 5440 clinical and preclinical compounds. Toxicity counterselection and challenge with the \u03b2-coronaviruses OC43 and SARS-CoV-2 in tissue culture and human airway epithelial explant cultures (HAEEC) identified four FDA-approved compounds with oral availability. Methylene blue (MB, used for the treatment of methemoglobinemia), Mycophenolic acid (MPA, used in organ transplantion) and the anti-fungal agent Posaconazole (POS) had the broadest anti-CoV spectrum. They inhibited the shedding of SARS CoV 2 and variants-of-concern (alpha, beta, gamma) from HAEEC in either pre- or post exposure regimens at clinically relevant dosage. Co-treatment of cultured cells with MB and the FDA-approved SARS-CoV-2 RNA-polymerase inhibitor Remdesivir reduced the effective anti-viral dosage of MB by 2-fold, and Remdesivir by 4 to 10-fold, indicated by BLISS independence syner-gy modelling. Neither MB, MPA or POS affected the cell delivery of SARS-CoV-2 or OC43 (+)sense RNA, but blocked subsequent viral RNA accumulation in cells. Unlike Remdesivir, MB, MPA or POS did not reduce the release of viral RNA in post exposure regimen, thus indicating infection inhibition at a post-replicating step as well. In summary, the data emphasize the power of unbiased, full cycle compound screens to identify and repurpose broadly acting drugs against coronaviruses.&lt;br&gt;&lt;br&gt;Funding Information: We acknowledge financial support from the Swiss National Science foundation (SNSF) to UFG and GT (31CA30_196177 \/ 1), the NCCR Chemical Biology supported by the SNSF for purchasing the BSF-EPFL repurposing collection, and a special Coronavirus Research grant from the University of Zurich to UFG. &lt;br&gt;&lt;br&gt;Declaration of Interests: UFG has been a consultant and stock owner in 3V-Biosciences (now Sagimet Biosciences), and a consultant to F. Hoffmann-La Roche Ltd. The authors filed a patent application on the use of MPA for the treatment of COVID-19 (EP20213904, European Patent Office, University of Zurich).&lt;br&gt;&lt;br&gt;Ethical Approval: Nasal polyp epithelial cells and bronchial epithelial cells were purchased from Epithelix SARL (Geneva, Switzerland). Mucilair\u2122 cells were reconstituted from patients undergoing surgical nasal polypectomy or bronchial biopsies, respectively. All samples from Epithelix SARL were obtained with informed consent, according to the declaration of Helsinki on biomedical research (Hong Kong amendment, 1989), and received approval from local ethics committee (commission cantonale d\u2019\u00e9thique de la recherche CCER de Gen\u00e8ve).&lt;br&gt;&lt;br&gt;Coronavirus storage and procedures have been registered and validated by the Swiss Federal Office for the Environment (Bundesamt f\u00fcr Umwelt, BAFU) and the Swiss Federal Office of Public Health (Bundesamt f\u00fcr Gesundheit, BAG); Ecogen A203032-00, registered the 01-Sep-2020 for a duration of 5-years for the University of Zurich (Department of Molecular Life Sciences).<\/jats:p>","DOI":"10.2139\/ssrn.3914634","type":"posted-content","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T23:07:49Z","timestamp":1631315269000},"source":"Crossref","is-referenced-by-count":0,"title":["Identification of Broad Anti-Coronavirus Chemical Agents for Repurposing Against SARS-CoV-2 and Variants of Concern"],"prefix":"10.2139","author":[{"given":"Luca","family":"Murer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Volle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vardan","family":"Andriasyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Petkidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Gomez-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliane","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Meili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarit","family":"Suomalainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Sequeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Olszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Georgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2575-1989","authenticated-orcid":true,"given":"Fabien","family":"Kuttler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Turcatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2278-120X","authenticated-orcid":true,"given":"Urs","family":"Greber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"ref1","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","article-title":"Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China","volume":"27","author":"A Wu","year":"2020","journal-title":"Cell host & microbe"},{"key":"ref2","journal-title":"COVID-19 Map -Johns Hopkins Coronavirus Resource Center"},{"issue":"5","key":"ref3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"L R Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"ref4","first-page":"99","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil","volume":"397","author":"M Voysey","year":"2021","journal-title":"South Africa, and the UK"},{"issue":"7871","key":"ref5","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization","volume":"596","author":"D Planas","year":"2021","journal-title":"Nature"},{"issue":"23","key":"ref6","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1056\/NEJMoa2105000","article-title":"Vaccine Breakthrough Infections with SARS-CoV-2 Variants","volume":"384","author":"E Hacisuleyman","year":"2021","journal-title":"N Engl J Med"},{"key":"ref7","author":"P Mlcochova"},{"key":"ref8","article-title":"Delta variant replication, sensitivity to neutralising antibodies and vaccine breakthrough","year":"2021","journal-title":"bioRxiv"},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.cell.2020.06.044","article-title":"Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients","volume":"182","author":"C Kreer","year":"2020","journal-title":"Cell"},{"issue":"13","key":"ref10","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/jama.2021.3199","article-title":"SARS-CoV-2 vaccines","volume":"325","author":"C B Creech","year":"2021","journal-title":"Jama"},{"key":"ref11","article-title":"Evaluation, and Treatment of Coronavirus (COVID-19)","author":"M Cascella","year":"2021","journal-title":"StatPearls. Treasure Island"},{"issue":"19","key":"ref12","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of Covid-19 -Final Report","volume":"383","author":"J H Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"ref13","article-title":"COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology","author":"M F Neurath","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"ref14","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"T T Ashburn","year":"2004","journal-title":"Nature reviews Drug discovery"},{"issue":"7827","key":"ref15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41586-020-2577-1","article-title":"Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing","volume":"586","author":"L Riva","year":"2020","journal-title":"Nature"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep35100","article-title":"Translation elongation factor eEF1A2 is a novel anticancer target for the marine natural product plitidepsin","volume":"6","author":"A Losada","year":"2016","journal-title":"Scientific reports"},{"issue":"6532","key":"ref17","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1126\/science.abf4058","article-title":"Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A","volume":"371","author":"K M White","year":"2021","journal-title":"Science"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002976","article-title":"Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects","volume":"8","author":"A Jurgeit","year":"2012","journal-title":"PLoS Pathog"},{"key":"ref19","author":"S S Good"},{"issue":"4","key":"ref20","article-title":"Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19","volume":"65","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"ref21","doi-asserted-by":"crossref","first-page":"e00171","DOI":"10.1128\/mBio.00171-10","article-title":"Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity","volume":"1","author":"L Cervantes-Barragan","year":"2010","journal-title":"MBio"},{"issue":"7813","key":"ref22","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-020-2294-9","article-title":"Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform","volume":"582","author":"Ttn Thao","year":"2020","journal-title":"Nature"},{"issue":"9","key":"ref23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138760","article-title":"0-a high-throughput analysis framework to score virus-cell transmission and clonal cell expansion","volume":"10","author":"A Yakimovich","year":"2015","journal-title":"PloS one"},{"issue":"9","key":"ref24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138760","article-title":"0-A High-Throughput Analysis Framework to Score Virus-Cell Transmission and Clonal Cell Expansion","volume":"10","author":"A Yakimovich","year":"2015","journal-title":"PLoS One"},{"key":"ref25","article-title":"SynergyFinder Plus: towards a better interpretation and annotation of drug combination screening datasets","author":"S Zheng","year":"2021","journal-title":"bioRxiv"},{"key":"ref26","author":"D Kim","journal-title":"The Architecture of SARS-CoV"},{"issue":"4","key":"ref27","volume":"181","year":"2020","journal-title":"Transcriptome. Cell"},{"issue":"9","key":"ref28","doi-asserted-by":"crossref","first-page":"e01002","DOI":"10.1128\/AAC.01002-20","article-title":"The FDA-approved drug nelfinavir inhibits lytic cell-free but not cell-associated nonlytic transmission of human adenovirus","volume":"64","author":"F Georgi","year":"2020","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"ref29","first-page":"1","volume":"7","author":"F Georgi","year":"2020","journal-title":"A highcontent image-based drug screen of clinical compounds against cell transmission of adenovirus. Scientific Data"},{"issue":"2","key":"ref30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"J-H Zhang","year":"1999","journal-title":"Journal of biomolecular screening"},{"issue":"4","key":"ref31","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nm.4306","article-title":"The Drug Repurposing Hub: a next-generation drug library and information resource","volume":"23","author":"S M Corsello","year":"2017","journal-title":"Nature medicine"},{"issue":"2","key":"ref32","article-title":"Rapid biochemical test for measuring chemical toxicity","volume":"26","author":"D Liu","year":"1981","journal-title":"Bull Environ Contam Toxicol"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep09054","article-title":"The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination","volume":"5","author":"F Maione","year":"2015","journal-title":"Scientific reports"},{"issue":"13","key":"ref34","doi-asserted-by":"crossref","first-page":"10236","DOI":"10.1074\/jbc.M111.321133","article-title":"Inhibitors of V-ATPase proton transport reveal uncoupling functions of tether linking cytosolic and membrane domains of V0 subunit a (Vph1p)","volume":"287","author":"C Y Chan","year":"2012","journal-title":"J Biol Chem"},{"issue":"7","key":"ref35","first-page":"588","article-title":"Efficacy of cetylpyridinium chloride used as oropharyngeal antiseptic","volume":"51","author":"F-A Pitten","year":"2001","journal-title":"Arzneimittelforschung"},{"issue":"5","key":"ref36","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.252544","article-title":"Cell-to-cell and genome-togenome variability of adenovirus transcription tuned by the cell cycle","volume":"134","author":"M Suomalainen","year":"2020","journal-title":"J Cell Sci"},{"issue":"8","key":"ref37","doi-asserted-by":"crossref","DOI":"10.3390\/v13081568","article-title":"Virus Infection Variability by Single-Cell Profiling","volume":"13","author":"M Suomalainen","year":"2021","journal-title":"Viruses"},{"issue":"41","key":"ref38","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1038\/s41388-018-0333-x","article-title":"Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia","volume":"37","author":"Y Zhang","year":"2018","journal-title":"Oncogene"},{"issue":"1","key":"ref39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/0091270010390807","article-title":"Use of an Adaptive Study Design in Single Ascending-Dose Pharmacokinetics of A0001 (?-Tocopherylquinone) in Healthy Male Subjects","volume":"52","author":"A Hawi","year":"2012","journal-title":"The Journal of Clinical Pharmacology"},{"issue":"7239","key":"ref40","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nature07884","article-title":"An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer","volume":"458","author":"T A Soucy","year":"2009","journal-title":"Nature"},{"key":"ref41","doi-asserted-by":"crossref","DOI":"10.1038\/srep09054","article-title":"The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination","volume":"5","author":"F Maione","year":"2015","journal-title":"Scientific reports"},{"issue":"4","key":"ref42","article-title":"Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia","volume":"1","author":"A Pizzorno","year":"2020","journal-title":"Cell Rep Med"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/bs.aivir.2018.01.001","article-title":"Hosts and sources of endemic human coronaviruses","volume":"100","author":"V M Corman","year":"2018","journal-title":"Advances in virus research"},{"key":"ref44","author":"N Oreshkova"},{"issue":"23","key":"ref45","article-title":"SARS-CoV-2 infection in farmed minks, the Netherlands","volume":"25","author":"R W Honing","year":"2020","journal-title":"Eurosurveillance"},{"issue":"1","key":"ref46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","article-title":"Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets","volume":"6","author":"R M Cox","year":"2021","journal-title":"Nature microbiology"},{"issue":"2","key":"ref47","doi-asserted-by":"crossref","first-page":"e00221","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"M L Agostini","year":"2018","journal-title":"MBio"},{"issue":"43","key":"ref48","doi-asserted-by":"crossref","first-page":"26946","DOI":"10.1073\/pnas.2012294117","article-title":"Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases","volume":"117","author":"M K Lo","year":"2020","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"541","key":"ref49","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"T P Sheahan","year":"2020","journal-title":"Science translational medicine"},{"issue":"6498","key":"ref50","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.abc1560","article-title":"Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir","volume":"368","author":"W Yin","year":"2020","journal-title":"Science"},{"issue":"11","key":"ref51","article-title":"Trends in clinical development timeframes for antiviral drugs launched in the UK, 1981-2014: a retrospective observational study","volume":"5","author":"D J Ward","year":"2015","journal-title":"BMJ open"},{"issue":"6","key":"ref52","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1128\/AAC.01295-10","article-title":"The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro","volume":"55","author":"S Gantt","year":"2011","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"6377","key":"ref53","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/357420a0","article-title":"Human aminopeptidase N is a receptor for human coronavirus 229E","volume":"357","author":"C L Yeager","year":"1992","journal-title":"Nature"},{"issue":"47","key":"ref54","doi-asserted-by":"crossref","first-page":"19970","DOI":"10.1073\/pnas.0908837106","article-title":"Crystal structure of NL63 respiratory coronavirus receptorbinding domain complexed with its human receptor","volume":"106","author":"K Wu","year":"2009","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"7","key":"ref55","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1073\/pnas.1809667116","article-title":"Human coronaviruses OC43 and HKU1 bind to 9-O-acetylated sialic acids via a conserved receptor-binding site in spike protein domain A","volume":"116","author":"R J Hulswit","year":"2019","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"6485","key":"ref56","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"R Yan","year":"2020","journal-title":"Science"},{"issue":"6518","key":"ref57","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.abd2985","article-title":"Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity","volume":"370","author":"L Cantuti-Castelvetri","year":"2020","journal-title":"Science"},{"issue":"6518","key":"ref58","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1126\/science.abd3072","article-title":"Neuropilin-1 is a host factor for SARS-CoV-2 infection","volume":"370","author":"J L Daly","year":"2020","journal-title":"Science"},{"issue":"2","key":"ref59","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00228-008-0563-x","article-title":"High absolute bioavailability of methylene blue given as an aqueous oral formulation","volume":"65","author":"I Walter-Sack","year":"2009","journal-title":"European journal of clinical pharmacology"},{"issue":"5","key":"ref60","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1179\/135100003225002899","article-title":"Methylene blue as an antimalarial agent","volume":"8","author":"R H Schirmer","year":"2003","journal-title":"Redox report"},{"issue":"4","key":"ref61","article-title":"Indian journal of critical care medicine: peer-reviewed, official publication of Indian Society of","volume":"18","author":"S Patnaik","year":"2014","journal-title":"Critical Care Medicine"},{"issue":"1","key":"ref62","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1128\/AAC.00773-07","article-title":"Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum","volume":"52","author":"K Buchholz","year":"2008","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"17","key":"ref63","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1089\/ars.2017.7342","article-title":"Transcriptional regulation by Nrf2","volume":"29","author":"C Tonelli","year":"2018","journal-title":"Antioxidants & redox signaling"},{"key":"ref64","article-title":"The endoplasmic reticulum unfolded protein responsehomeostasis, cell death and evolution in virus infections","author":"V Prasad","year":"2021","journal-title":"FEMS Microbiology Reviews"},{"issue":"1","key":"ref65","first-page":"1","article-title":"SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate","volume":"11","author":"D Olagnier","year":"2020","journal-title":"Nature communications"},{"issue":"5","key":"ref66","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1517\/14728222.11.5.695","article-title":"Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery","volume":"11","author":"J A Khan","year":"2007","journal-title":"Expert opinion on therapeutic targets"},{"issue":"1","key":"ref67","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-24521-x","article-title":"SARS-CoV-2 infection induces the dedifferentiation of multiciliated cells and impairs mucociliary clearance","volume":"12","author":"R Robinot","year":"2021","journal-title":"Nat Commun"},{"issue":"7","key":"ref68","article-title":"Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19","volume":"4","author":"M E Ohl","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"3","key":"ref69","first-page":"190","article-title":"Methylene Blue for Treatment of Hospitalized Covid-19 Patients: A Randomized, Controlled, Open-Label Clinical Trial, Phase 2","volume":"73","author":"D Hamidi-Alamdari","year":"2021","journal-title":"Rev Invest Clin"},{"issue":"7","key":"ref70","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1111\/jdv.16491","article-title":"Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases?","volume":"34","author":"Di Altobrando","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref71","article-title":"Occurrence of SARS-CoV-2 during mycophenolate mofetil treatment for pemphigus","author":"R Balestri","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"ref72","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.10.004","article-title":"SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to Suppress Host Defenses","volume":"183","author":"A K Banerjee","year":"2020","journal-title":"Cell"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"P Mehta","year":"2020","journal-title":"Lancet"},{"issue":"7841","key":"ref74","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2901-9","article-title":"Identification of SARS-CoV-2 inhibitors using lung and colonic organoids","volume":"589","author":"Y Han","year":"2021","journal-title":"Nature"},{"issue":"7","key":"ref75","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1021\/cr900021w","article-title":"Hedstrom L. IMP dehydrogenase: structure, mechanism, and inhibition","volume":"109","year":"2009","journal-title":"Chemical reviews"},{"issue":"9","key":"ref76","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1073\/pnas.0808790106","article-title":"Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase","volume":"106","author":"Y Chen","year":"2009","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"1","key":"ref77","article-title":"The emergence of mycophenolate mofetilin dermatology: from its roots in the world of organ transplantation to its versatile role in the dermatology treatment room","volume":"4","author":"H Park","year":"2011","journal-title":"The Journal of clinical and aesthetic dermatology"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cytogfr.2020.05.003","article-title":"The cytokine storm in COVID-19: An overview of the involvement of the chemokine\/chemokine-receptor system","volume":"53","author":"F Coperchini","year":"2020","journal-title":"Cytokine & growth factor reviews"},{"issue":"19","key":"ref79","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19","volume":"383","author":"J H Beigel","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"ref80","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41577-020-00421-x","article-title":"After 62 years of regulating immunity, dexamethasone meets COVID-19","volume":"20","author":"D W Cain","year":"2020","journal-title":"Nature Reviews Immunology"},{"issue":"2","key":"ref81","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-3083.1991.tb03747.x","article-title":"Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice","volume":"33","author":"E M Eugui","year":"1991","journal-title":"Scandinavian journal of immunology"},{"issue":"11","key":"ref82","doi-asserted-by":"crossref","first-page":"26654","DOI":"10.3390\/ijms161125985","article-title":"Mycophenolate mofetil modulates differentiation of Th1\/Th2 and the secretion of cytokines in an active Crohn's disease mouse model","volume":"16","author":"Q-K Lv","year":"2015","journal-title":"International journal of molecular sciences"},{"key":"ref83","first-page":"497","volume":"395","author":"C Huang","year":"2020","journal-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet"},{"issue":"12","key":"ref84","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1517\/14656566.4.12.2325","article-title":"Mycophenolate mofetil in solid-organ transplantation","volume":"4","author":"T R Srinivas","year":"2003","journal-title":"Expert opinion on pharmacotherapy"},{"issue":"3","key":"ref85","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1124\/mol.65.3.744","article-title":"SB-505124 is a selective inhibitor of transforming growth factor-? type I receptors ALK4, ALK5, and ALK7","volume":"65","author":"S D Byfield","year":"2004","journal-title":"Molecular pharmacology"},{"key":"ref86","author":"P A Mann","journal-title":"Mutations in Aspergillus fumigatus resulting in reduced susceptibility"},{"issue":"2","key":"ref87","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1128\/AAC.47.2.577-581.2003","volume":"47","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"16","key":"ref88","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.2174\/156802611796575902","article-title":"Sterol 14alpha-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasis","volume":"11","author":"G I Lepesheva","year":"2011","journal-title":"Curr Top Med Chem"},{"issue":"10","key":"ref89","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1128\/AAC.40.10.2237","article-title":"In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum","volume":"40","author":"K Hata","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"ref90","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0022-2275(20)37449-6","article-title":"3-oxidosqualene: lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin","volume":"2","author":"O H Morand","year":"1997","journal-title":"Journal of lipid research"},{"issue":"12","key":"ref91","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003056","article-title":"Threedimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication","volume":"8","author":"I Romero-Brey","year":"2012","journal-title":"PLoS pathogens"},{"issue":"1","key":"ref92","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1128\/JVI.05937-11","article-title":"Complex dynamic development of poliovirus membranous replication complexes","volume":"86","author":"G A Belov","year":"2012","journal-title":"Journal of virology"},{"issue":"5","key":"ref93","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.chom.2014.10.003","article-title":"Rhinovirus uses a phosphatidylinositol 4-phosphate\/cholesterol counter-current for the formation of replication compartments at the ER-Golgi interface","volume":"16","author":"P S Roulin","year":"2014","journal-title":"Cell host & microbe"},{"issue":"1","key":"ref94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41420-020-0237-8","article-title":"Preclinical studies reveal MLN4924 is a promising new retinoblastoma therapy","volume":"6","author":"A Aubry","year":"2020","journal-title":"Cell death discovery"},{"issue":"7239","key":"ref95","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nature07884","article-title":"An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer","volume":"458","author":"T A Soucy","year":"2009","journal-title":"Nature"},{"issue":"1","key":"ref96","first-page":"1","article-title":"Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells","volume":"6","author":"H Lan","year":"2016","journal-title":"Scientific reports"},{"issue":"17","key":"ref97","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1089\/ars.2013.5795","article-title":"Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy","volume":"21","author":"Y Zhao","year":"2014","journal-title":"Antioxidants & redox signaling"},{"issue":"8","key":"ref98","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2020.100137","article-title":"A high-content screen for mucin-1-reducing compounds identifies fostamatinib as a candidate for rapid repurposing for acute lung injury","volume":"1","author":"M Kost-Alimova","year":"2020","journal-title":"Cell Reports Medicine"},{"issue":"8","key":"ref99","doi-asserted-by":"crossref","DOI":"10.3390\/ph13080196","article-title":"Avermectin derivatives, pharmacokinetics, therapeutic and toxic dosages, mechanism of action, and their biological effects","volume":"13","author":"G El-Saber Batiha","year":"2020","journal-title":"Pharmaceuticals"},{"key":"ref100","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.561334","article-title":"Anti-SARS-CoV natural products with the potential to inhibit SARS-CoV-2 (COVID-19)","volume":"11","author":"S Verma","year":"2020","journal-title":"Frontiers in Pharmacology"},{"issue":"4","key":"ref101","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125028","article-title":"Activating the Wnt\/?-catenin pathway for the treatment of melanoma-application of LY2090314, a novel selective inhibitor of glycogen synthase kinase-3","volume":"10","author":"J M Atkinson","year":"2015","journal-title":"PloS one"},{"issue":"12","key":"ref102","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.chembiol.2003.11.010","article-title":"GSK-3-selective inhibitors derived from Tyrian purple indirubins","volume":"10","author":"L Meijer","year":"2003","journal-title":"Chemistry & biology"},{"issue":"1","key":"ref103","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1021\/jm101157q","article-title":"Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family","volume":"54","author":"G Thoma","year":"2011","journal-title":"Journal of medicinal chemistry"},{"issue":"3","key":"ref104","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.bone.2011.11.007","article-title":"GSK-3 inhibition by an orally active small molecule increases bone mass in rats","volume":"50","author":"R Marsell","year":"2012","journal-title":"Bone"},{"issue":"3","key":"ref105","doi-asserted-by":"crossref","first-page":"588","DOI":"10.2337\/diabetes.52.3.588","article-title":"Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo","volume":"52","author":"D B Ring","year":"2003","journal-title":"Diabetes"},{"issue":"2","key":"ref106","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.tibs.2003.12.004","article-title":"The glamour and gloom of glycogen synthase kinase-3","volume":"29","author":"R S Jope","year":"2004","journal-title":"Trends in biochemical sciences"},{"issue":"6","key":"ref107","doi-asserted-by":"crossref","DOI":"10.3390\/cells9061427","article-title":"The role of GSK-3 in cancer immunotherapy: GSK-3 inhibitors as a new frontier in cancer treatment","volume":"9","author":"G Augello","year":"2020","journal-title":"Cells"},{"key":"ref108","author":"X Liu","year":"2021","journal-title":"Targeting the Coronavirus Nucleocapsid Protein through GSK-3 Inhibition. medRxiv"},{"key":"ref109","author":"(a-B) Remdesivir","journal-title":"Not determined (nd) indicates virus titers below 2.4 log10 TCID50\/ml in the two replicates, and (1\/2) indicates virus titers below 2"},{"key":"ref110","journal-title":"The SARS-CoV-2 RT-qPCR inter-assay reproducibility is represented with the linear regression curve generated by plotting the Ct values against the copy numbers (106 to 103 copies per \ufffdl) of the RNA quantitative standards in 8-independent replicates. The coefficient of correlation (CV) was calculated for each quantitative point according to the formula: %CV= (SD \/ Ct mean)\ufffd100"},{"key":"ref111","author":"Sars-Cov2"},{"key":"ref112","author":"Thi Nhu","year":"2020","journal-title":"Nature"},{"key":"ref113","first-page":"V4","author":"N\/A Sars-Cov2 Beta"},{"key":"ref114","journal-title":"RIVM (through EVaG) Not available anymore Human: H1299 Kindly provided by Dr. Silvio Hemmi (University of Zurich, Switzerland) human airway epithelium cells (hAEC)"},{"key":"ref115","article-title":"Bronchial Epithelix MucilAir\ufffd Cat #EP01 Single donor; lot# MD0810 Software and Algorithms Graphpad Prism GraphPad Software","volume":"8","journal-title":"lot#MP009 human airway epithelium cells (hAEC)"},{"key":"ref116","journal-title":"Greber Laboratory"}],"container-title":[],"original-title":[],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T16:19:33Z","timestamp":1786637973000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ssrn.com\/abstract=3914634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":116,"URL":"https:\/\/doi.org\/10.2139\/ssrn.3914634","relation":{},"subject":[],"published":{"date-parts":[[2021]]},"subtype":"preprint"}}